TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32766808
Drug: Osteopathic Manipulative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osteopathic Manipulative Medicine (OMM)
Study: 34022937
Drug: Single-dose tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose tranexamic acid
Study: 36201813
Drug: Internet-delivered treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-delivered treatment for anxiety and depression over 8 weeks
Study: 34503735
Drug: HER2-targeted therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HER2-targeted therapy
Study: 33676429
Drug: Blended AUD
Normalized name: Io-Blend
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blended AUD treatment
Study: 33676429
Drug: Face-to-face treatment
Normalized name: FACE SHIELD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Face-to-face treatment only (TAU)
Study: 34801738
Drug: Umifenovir (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Umifenovir (800 mg BID, maximum 14 days)
Study: 36426809
Drug: Morphine (group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (group M)
Study: 35941536
Drug: Oxycodone (group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone (group O)
Study: 32692113
Drug: Antiretroviral Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral Therapy (ART)
Study: 36200632
Drug: Direct-to-consumer advertising
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct-to-consumer advertising for heart disease medications (treatment 1)
Study: 36200632
Drug: Direct-to-consumer advertising
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct-to-consumer advertising for heart disease medications with price disclosure (treatment 2)
Study: 34147912
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate nasal spray (100 mcg twice daily) with olfactory training for 4 weeks
Study: 32066345
Drug: Linear accelerator
Normalized name: Aspalathus linearis leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linear accelerator (standard treatment)
Study: 33279295
Drug: Quiet group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quiet group (treatment)
Study: 35669313
Drug: Depot Medroxyprogesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depot Medroxyprogesterone Acetate Intramuscular Injection (DMPA-IM)
Study: 35669313
Drug: Levonorgestrel Implant
Normalized name: levonorgestrel IMPLANT KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levonorgestrel Implant (LNG)
Study: 32840417
Drug: Pazopanib 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazopanib 800 mg once per day
Study: 34815708
Drug: Galcanezumab 120
Normalized name: Galcanezumab 120 mg/mL solution for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galcanezumab 120 mg
Study: 32930994
Drug: Open-label treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label treatment (previous placebo)
Study: 32888343
Drug: Electronic tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electronic tablets
Study: 35554079
Drug: TrimRox, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: TrimRox, a stimulant‐ and sugar‐free Prodosomed® TRCAP21 nutraceutical technology, utilizing six standardized extracts.
Study: 38281089
Drug: Direct oral
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct oral anticoagulants (DOACs)
Study: 34585215
Drug: Multiple doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses 10 mg/kg every 4 weeks for 72 weeks
Study: 34585215
Drug: Multiple doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses 20 mg/kg every 4 weeks for 72 weeks
Study: 34379025
Drug: Placebo 3300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 3300 mg/day
Study: 34952747
Drug: Culturally tailored
Normalized name: casein, emmental cultured
Approvals — FDA: no, EMA: no, PMDA: no
Description: Culturally tailored contingency management (CM) intervention targeting alcohol abstinence; 12 weeks duration, incentives for negative urine tests (EtG < 150 ng/mL)
Study: 33043352
Drug: Autologous concentrated
Normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous concentrated growth factor fibrin solution + Bio‐Oss bone powder
Study: 34217230
Drug: Tailored intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tailored intervention to reduce inappropriate psychotropic drug use
Study: 34445969
Drug: Patient decision
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient decision aid (DA) on treatment of depression
Study: 34445969
Drug: Matched treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched treatment preference
Study: 34872085
Drug: Blood kidney
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood kidney injury molecule 1 (KIM-1)
Study: 35983809
Drug: Tadalafil 5
Normalized name: tadalafil 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil 5 mg every 3 days
Study: 39665506
Drug: Methylphenidate (20
Normalized name: methylphenidate (20/80 release) 25 mg/24 hr oral capsule, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (20 mg)
Study: 34302350
Drug: Prenatal cholecalciferol
Normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prenatal cholecalciferol (vitamin D-3) dose of 0, 4200, 16,800, or 28,000 IU/wk from 17 to 24 wk of gestation followed by placebo to 6 mo postpartum
Study: 34302350
Drug: Various biological,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various biological, sociodemographic, and laboratory-related characteristics including feeding practices
Study: 33648870
Drug: Renal-specific oral
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Renal-specific oral nutritional supplement (RS-ONS) during hemodialysis sessions, given in two portions: 100 mL after 1 hour and 137 mL 45 minutes before the end of hemodialysis.
Study: 33648870
Drug: Renal-specific oral
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Renal-specific oral nutritional supplement (RS-ONS) at home.
Study: 32960094
Drug: Ethanol 86%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol 86% v/v gel
Study: 32960094
Drug: Ethanol 89.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol 89.5% v/v solution
Study: 32960094
Drug: Ethanol 72.4%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol 72.4% v/v solution
Study: 32960094
Drug: Reference solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference solution (70% v/v ethanol)
Study: 32428656
Drug: Herbal medicine
Normalized name: Herbal medicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal medicine use
Study: 32428656
Drug: Factors associated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Factors associated with herbal medicine use
Study: 39621424
Drug: Sham therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham therapy
Study: 35856224
Drug: Empagliflozin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin (10 mg, once a day, orally)
Study: 33024552
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea (three cups/day after meals) + usual treatment (deferasirox iron chelator and on demand blood transfusion)
Study: 33024552
Drug: Control (only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (only usual treatment)
Study: 32123197
Drug: Nx4 (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nx4 (three tablets)
Study: 35201674
Drug: Erenumab 70
Normalized name: Erenumab 70 mg/mL solution for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erenumab 70 mg (EM)
Study: 35201674
Drug: Erenumab 70
Normalized name: Erenumab 70 mg/mL solution for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erenumab 70 mg (overall population)
Study: 35582897
Drug: Dextrose gel
Normalized name: Dextrose
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextrose gel followed by breastfeeding
Study: 32321172
Drug: Heparin prophylaxis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin prophylaxis
Study: 37266993
Drug: High-dose corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose corticosteroids
Study: 33452923
Drug: 6‐mg dexamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6‐mg dexamethasone (4 × 6‐mg)
Study: 33452923
Drug: 12‐mg dexamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12‐mg dexamethasone (2 × 12‐mg)
Study: 32961542
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg memantine
Study: 33136047
Drug: 50 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 Gy radiation dose (1 fractioned dose of 2 Gy per day, 5 days per week, for 5 weeks)
Study: 33136047
Drug: 70 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 70 Gy radiation dose (1 fractioned dose of 2 Gy per day, 5 days per week, for 7 weeks)
Study: 33136047
Drug: 50 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 Gy radiation dose
Study: 33136047
Drug: 70 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 70 Gy radiation dose
Study: 35293068
Drug: Oleoylethanolamide (OEA)
Normalized name: Palmitoylethanolamide
DrugBank: Oleic monoethanolamide (DB16495)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oleoylethanolamide (OEA) 125 mg per day for 2 months
Study: 39060905
Drug: Tumor necrosis
Normalized name: Tumor necrosis factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tumor necrosis factor inhibitors (TNFi)
Study: 39300794
Drug: Dupilumab 300
Normalized name: dupilumab 300 MG in 2 ML Auto-Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dupilumab 300 mg every 2 weeks
Study: 36958470
Drug: Dupilumab 200
Normalized name: dupilumab 200 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dupilumab 200 mg every 2 weeks
Study: 33058901
Drug: Computer VR-agent
Normalized name: Prostin VR
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Computer VR-agent exclusion
Study: 32651467
Drug: Nivolumab (anti-PD-1)
Normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab (anti-PD-1) administered every two weeks for four cycles (two cycles prior to first HDR, two cycles prior to second HDR) combined with androgen deprivation therapy (ADT) and high-dose-rate (HDR) brachytherapy.
Study: 32911988
Drug: High-dose vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vitamin D (600 IU/day plus 50,000 IU/week)
Study: 32911988
Drug: Low-dose vitamin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose vitamin D (600 IU/day plus placebo weekly)
Study: 32621898
Drug: Capsule tension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule tension ring (in PEX group)
Study: 32621898
Drug: No capsule
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No capsule tension ring (in PEX group)
Study: 32504574
Drug: Dolutegravir 50
Normalized name: dolutegravir 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolutegravir 50 mg, abacavir 600 mg, and lamivudine 300 mg
Study: 37429432
Drug: Continuous subcutaneous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous subcutaneous insulin infusion
Study: 35895381
Drug: Nivolumab (360
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab (360 mg) + gemcitabine and cisplatin (days 1 and 8 every 3 weeks for 6 months) followed by nivolumab (240 mg every 2 weeks)
Study: 35578360
Drug: Dalbavancin (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalbavancin (two doses on days 1 and 8)
Study: 35578360
Drug: Standard intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard intravenous antibiotic therapy (4–8 weeks)
Study: 35332558
Drug: Inebilizumab 300
Normalized name: INEBILIZUMAB
DrugBank: Inebilizumab (DB12530)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Inebilizumab 300 mg intravenous dose administered on Day 1 and Day 15 and every 6 months thereafter
Study: 33735712
Drug: Lopinavir/Ritonavir (800/200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lopinavir/Ritonavir (800/200 mg daily)
Study: 34482574
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of omega-3 fatty acids (300 mg daily) and vitamin D3 (50,000 IU weekly)
Study: 34482574
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acids supplementation (300 mg daily)
Study: 32334551
Drug: 42.5 g
Normalized name: PETROLATUM 57.3 g in 100 g / MINERAL OIL 42.5 g in 100 g OPHTHALMIC OINTMENT [MOISTU-EYES]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 42.5 g of almonds per day
Study: 32400122
Drug: Antiplatelet/Anticoagulant therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiplatelet/Anticoagulant therapy
Study: 32400122
Drug: Antiplatelet/Anticoagulant therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiplatelet/Anticoagulant therapy in lowest platelet quartile
Study: 33087047
Drug: IVIg (human)
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IVIg (human) - four vials daily for 3 days
Study: 38717556
Drug: Beta blockers
Normalized name: BETA BLOCKERS/RELATED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta blockers
Study: 33210444
Drug: Salmeterol 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol 400 μg
Study: 33891194
Drug: Eribulin (1.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eribulin (1.4 mg/m2 on day one and eight of each 21-day cycle)
Study: 33891194
Drug: Treatment of
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of physician’s choice (TPC) including paclitaxel, docetaxel, nab-paclitaxel or vinorelbine
Study: 33891194
Drug: Treatment of
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of physician’s choice (TPC)
Study: 32857051
Drug: Curry solution
Normalized name: CURRY RED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curry solution (distilled water with curry powder containing turmeric)
Study: 33145841
Drug: TAS-303 (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAS-303 (3 mg and 6 mg)
Study: 35758017
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate (NaHCO3) 0.3 g/kg body mass
Study: 35105570
Drug: Colchicine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine (0.5 mg daily for 3 days before surgery and 0.5 mg daily for 5 days after surgery)
Study: 33689854
Drug: Radical radiation
Normalized name: Campsis radicans flower extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radical radiation therapy with carbogen (98% O2; 2% CO2) and nicotinamide (CON)
Study: 33689854
Drug: Radical radiation
Normalized name: Campsis radicans flower extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radical radiation therapy alone (RT)
Study: 33689854
Drug: Radical radiation
Normalized name: Campsis radicans flower extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radical radiation therapy with CON in patients with tumor necrosis
Study: 33689854
Drug: Radical radiation
Normalized name: Campsis radicans flower extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radical radiation therapy with CON in patients with high hypoxia gene score
Study: 32473817
Drug: Overall performance
Normalized name: Perform
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall performance of treatment centers
Study: 32441302
Drug: Costoclavicular approach
Approvals — FDA: no, EMA: no, PMDA: no
Description: Costoclavicular approach (CC) with modified double-injection technique
Study: 32441302
Drug: Supraclavicular approach
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supraclavicular approach (SC) with modified double-injection technique
Study: 36451509
Drug: Conventional intradermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional intradermal acupuncture
Study: 33624081
Drug: Boosted protease
Normalized name: protease
Approvals — FDA: no, EMA: no, PMDA: no
Description: Boosted protease inhibitor (bPI) plus lamivudine dual therapy
Study: 33624081
Drug: Boosted protease
Normalized name: protease
Approvals — FDA: no, EMA: no, PMDA: no
Description: Boosted protease inhibitor (bPI) monotherapy
Study: 33624081
Drug: Dual therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual therapy (bPI + lamivudine)
Study: 34027782
Drug: Foley’s‐misoprostol (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foley’s‐misoprostol (25 µg vaginal misoprostol tablet)
Study: 34013839
Drug: L-Citrulline supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-Citrulline supplementation
Study: 35699910
Drug: Dapagliflozin (SGLT2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin (SGLT2 inhibitor)
Study: 33260196
Drug: Yoga intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Yoga intervention (daily sessions for one week)
Study: 34019729
Drug: DGC-CC
Approvals — FDA: no, EMA: no, PMDA: no
Description: DGC-CC
Study: 33546020
Drug: Shenfu injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenfu injection combined with furosemide
Study: 34719869
Drug: ADEB (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADEB (standard chemotherapy plus bortezomib)
Study: 34719869
Drug: ADE (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADE (standard chemotherapy without bortezomib)
Study: 36284289
Drug: Depth of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depth of anesthesia set to BIS 45 (group L)
Study: 33725323
Drug: Rivaroxaban (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban (2.5 mg twice daily) plus Aspirin (100 mg once daily)
Study: 38320511
Drug: Aspirin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (100 mg once daily)
Study: 36115497
Drug: Inhaled treprostinil
Normalized name: treprostinil Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled treprostinil (high dose, ≥9 breaths per session)
Study: 36115497
Drug: Inhaled treprostinil
Normalized name: treprostinil Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled treprostinil (low dose, <9 breaths per session)
Study: 36115497
Drug: Placebo (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (high dose)
Study: 36115497
Drug: Placebo (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (low dose)
Study: 35436940
Drug: Acetaminophen (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (1000 mg)
Study: 38290758
Drug: Conventional colonoscopy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional colonoscopy (CC)
Study: 33855080
Drug: Control (fixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (fixed dose of 1000 mL crystalloid fluid)
Study: 34906619
Drug: Mandibular single-implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mandibular single-implant overdentures (1-IODs)
Study: 32527501
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg kg−1 methylprednisolone in 5 mL of saline
Study: 32527501
Drug: 5 mL
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mL of saline (Control Group)
Study: 35027153
Drug: Interpersonal-focused therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interpersonal-focused therapy
Study: 33104519
Drug: Rg1 (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rg1 (5 mg, an immunostimulant ginsenoside)
Study: 35365305
Drug: STEP‐KOA (internet‐based
Approvals — FDA: no, EMA: no, PMDA: no
Description: STEP‐KOA (internet‐based exercise training program, phone counseling, physical therapy)
Study: 33678513
Drug: Edasalonexent 67
Normalized name: Edasalonexent
DrugBank: Edasalonexent (DB15010)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edasalonexent 67 mg/kg/day
Study: 33678513
Drug: Placebo or
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo or off-treatment control
Study: 34941114
Drug: Nebulized enriched
Normalized name: Hydra-Neb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized enriched heparin (2.5 mg/mL 0.9% saline)
Study: 35817323
Drug: 40 Gy/15
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 Gy/15 fractions/3 weeks (standard treatment)
Study: 35817323
Drug: 26 Gy/5
Approvals — FDA: no, EMA: no, PMDA: no
Description: 26 Gy/5 fractions/1 week (novel treatment)
Study: 35817323
Drug: 12 Gy/4
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 Gy/4 fractions/4 days (sequential boost)
Study: 36231152
Drug: Ashwagandha (ASH)
Normalized name: ASH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ashwagandha (ASH) 400 mg
Study: 35156040
Drug: Therapist‐assisted cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapist‐assisted cognitive behavioral therapy for insomnia
Study: 34085549
Drug: Intravenous dexketoprofen
Normalized name: dexketoprofen
DrugBank: Dexketoprofen (DB09214)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dexketoprofen
Study: 34762528
Drug: Bosentan (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bosentan (125 mg twice a day for 3 days)
Study: 34194732
Drug: 2.5% chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5% chlorhexidine solution and 0.9% NaCl
Study: 32805205
Drug: 12 μg
Normalized name: penicillin G 12 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 μg lubiprostone
Study: 33295809
Drug: Lorazepam (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam (0.05 mg/kg bolus followed by 4-h normal saline infusion)
Study: 32726499
Drug: Nifedipine GITS
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine GITS 30 mg administered in the morning (N-M)
Study: 32726499
Drug: Nifedipine GITS
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine GITS 30 mg administered at night (N-N)
Study: 32726499
Drug: Amlodipine besylate
Normalized name: Amlodipine Besylate
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine besylate 5 mg administered in the morning (A-M)
Study: 32726499
Drug: Amlodipine besylate
Normalized name: Amlodipine Besylate
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine besylate 5 mg administered at night (A-N)
Study: 34507102
Drug: CDP-choline (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDP-choline (2 g/day for 8 weeks)